Table 2 Comparison of remission rate according to patient’s clinical characteristics.

	Patients no.	Remission no. (%)	95% CI	χ²	p Value
Overall	47	38 (80.9)	69.2–92.5
Sex				2.415	0.120
M	23	16 (69.6)	49.2–89.9
F	24	22 (91.7)	79.7–103.6
Age				0.036	0.850
Pediatric cohort (<14 y)	17	13 (76.5)	54.0–99.0
Adult cohort (≥14 y)	30	25 (83.3)	69.2–97.5
Previous allo-HSCT				0.044	0.833
Yes	9	8 (88.9)	63.3–114.5
No	38	30 (78.9)	65.4–92.5
Times of previous chemotherapy				0.424	0.515
≥10	19	14 (73.7)	51.9–95.5
<10	28	24 (85.7)	71.9–99.5
Refractory				–	1.000^a
Yes	3	3 (100.0)	100.0
No	44	35 (79.5)	67.1–92.0
Times of relapse				0.214	0.643
1	25	21 (84.0)	68.6~99.4
≥2	19	14 (73.7)	51.9–95.5
Percentage of marrow blasts ≥ 5%				0	1.000
Yes	32	26 (81.3)	67.0–95.5
No	15	12 (80.0)	57.1–102.9
Percentage of marrow blasts ≥ 20%				0.151	0.698
Yes	26	20 (76.9)	59.6–94.3
No	21	18 (85.7)	69.4–102.0
High-risk cytogenetic factors^b				–	0.655^a
Yes	28	23 (82.1)	67.0–97.3
No	11	10 (90.9)	70.7–111.2
Active EMDs before infusion				6.225	0.013^c
Yes	13	7 (53.8)	22.5–85.2
No	34	31 (91.2)	81.1–101.2
Subgroup 1: CNS involvement only vs. no-EMDs				–	0.493^a
CNS involvement	6	5 (83.3)	40.5–126.2
No-EMDs	34	31 (91.2)	81.1–101.2
Subgroup 2: CNS involvement only vs. EMDs other than CNS^d				–	0.103^a
CNS involvement only	6	5 (83.3)	40.5–126.2
EMDs other than CNS	7	2 (28.6)	−16.6 to 73.7
Subgroup 3: EMDs other than CNS vs. no-EMDs				10.775	0.001^c
EMDs other than CNS	7	2 (28.6)	−16.6 to 73.7
No-EMDs	34	31 (91.2)	81.1–101.2
Tregs before infusion^e				0.605	0.437
Higher cohort	28	21 (75.0)	57.9–92.1
Normal or lower cohort	18	16 (88.9)	72.8–105.0

^aFisher’s exact test
^bThree patients did not have data on genetic factors, and five patients had cytogenetic/molecular abnormalities of undetermined significance.
^cCompared with patients without EMDs, the CR/CRi rate in patients with EMDs was significantly lower (91.2% vs. 53.8%, p = 0.013) with a statistical power of 82.9%, the CR/CRi rate in patients with EMDs other than CNS was the lowest (91.2% vs. 28.6%, p = 0.001) with a statistical power of 96.8%, but the CR/CRi rate in patients with CNS involvement only had no significant difference (91.2% vs. 83.3%, p = 0.493) with a statistical power of 9.1%.
^dThe locations of these EMDs other than CNS, include three patients with bone and soft tissue multiple locally involvement, two with testicular involvement, one in the right breast, and one in local bone concurrently with CNS involvement.
^eTregs data were not available for one patient.
A two-sided Pearson chi-squared test (or Fisher’s exact test) was used for comparison between groups. Source data is provided as a Source Data file or available at https://doi.org/10.6084/m9.figshare.13136078.v1.

Search